Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers

Neurology

Volumn 73, Issue 23, 2009, Pages 2011-2017

  McCann, Una D ^a   Sgambati, Francis P ^a   Schwartz, Alan R ^b   Ricaurte, George A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; APNEA; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NONREM SLEEP; OBESITY; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RACE; SLEEP APNEA SYNDROME;

EID: 73349101012     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c51a62     Document Type: Article

References (37)

1. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing in collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008;118:1080-1111.
2. Pack AI. Advances in sleep-disordered breathing. Am J Re-spir Crit Care Med 2006;173:7-15.
3. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008;31:1071-1078.
4. Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008;31:1079-1085.
5. Challet E. Minireview: entrainment of the suprachiasmatic clockwork in diurnal and nocturnal mammals. Endocrinology 2007;148:5648-5655.
6. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005;437:1257-1263. (Pubitemid 41568665)
7. Richerson GB. Serotonergic neurons as carbon dioxide sensors that maintain pH homeostasis. Nat Rev Neurosci 2004;5:449-461.
8. Veasey SC. Serotonin agonists and antagonists in obstructive sleep apnea: therapeutic potential. Am J Respir Med 2003;2:21-29.
9. Volgin DV, Fay R, Kubin L. Postnatal development of serotonin 1B, 2 A and 2C receptors in brainstem motoneu-rons. Eur J Neurosci 2003;17:1179-1188.
10. Horner RL. Control of genioglossus muscle by sleep state-dependent neuromodulators. Adv Exp Med Biol 2008; 605:262-267.
11. Horner RL. Neuromodulation of hypoglossal motoneurons during sleep. Respir Physiol Neurobiol 2008;164:179-196.
12. Tryba AK, Peña F, Ramirez JM. Gasping activity in vitro: a rhythm dependent on 5-HT2A receptors. J Neurosci 2006;26:2623-2634.
13. Mahamed S, Mitchell GS. Simulated apnoeas induce serotonin-dependent respiratory long-term facilitation in rats. J Physiol 2008;586:2171-2181.
14. Eckert DJ, Malhotra A, Jordan AS. Mechanisms of apnea. Prog Cardiovasc Dis 2009;51:313-323.
15. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 2003;55:463-508.
16. Gudelsky GA, Yamamoto BK. Actions of 3,4-meth-ylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 2008;90:198-207.
17. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Mol-liver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988;8:2788-2803.
18. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999;19:5096-5107.
19. McCann UD, Szabo Z, Seckin E, et al. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [ C]McN5652 and [ C]DASB. Neuro-psychopharmacology 2005;30:1741-1750.
20. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br J Psychiatry 1999;176:63-69.
21. Thomasius R, Zapletalova P, Petersen K, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 2006;20:211-225.
22. McCann UD, Ricaurte GA. Effects of ( + /-) 3,4- methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms. Sci World J 2007;7:231-238.
23. Parrott AC. Human research on MDMA (3,4-methylene-dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 2000; 42:17-24.
24. Zakzanis KK, Campbell Z, Jovanovski D. The neuropsychology of ecstasy (MDMA) use: a quantitative review. Hum Psychopharmacol 2007;22:427-435.
25. Kalechstein AD, De La Garza R II, Mahoney JJ III, Fante-grossi WE, Newton TF. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology 2007;189: 531-537.
26. de Win MM, Jager G, Booij J, et al. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 2008;131(pt 11):2936-2945.
27. McCann UD, RidenourA, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (+/-) 3,4-methylenedioxy-methamphetamine (MDMA; "ecstasy"): a controlled study in humans. Neuropsychopharmacology 1994;10:129-138.
28. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), clinician version. Arlington, VA: American Psychiatric Publishing Inc; 1997.
29. Iber C, Ancoli-Israel S, Chesson AL, Quan SF. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications. Westchester, IL: American Academy of Sleep Medicine; 2007.
30. Morgan MJ, Impallomeni LC, Pirona A, Rogers RD. Elevated impulsivity and impaired decision-making in abstinent ecstasy (MDMA) users compared to polydrug and drug-naive controls. Neuropsychopharmacology 2006;31:1562-1573.
31. Quednow BB, Kühn KU, Hoppe C, Westheide J, Maier W, Daum I, Wagner M. Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("ecstasy"). Psychopharmacology 2007;189:517-530.
32. McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricau-rte GA. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymetha-mphetamine (MDMA) users. Psychopharmacology 1999; 147:56-65.
33. Gerra G, Zaimovic A, Ferri M, et al. Long-lasting effects of ( + /-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 2000;47:127-136.
34. Banks S, Dinges DF. Behavioral and physiological consequences of sleep restriction. J Clin Sleep Med 2007;3: 519-528.
35. Carskadon MA, Acebo C, Jenni OG. Regulation of adolescent sleep: implications for behavior. Ann NY Acad Sci 2004;1021:276-291.
36. O'Brien EM, Mindell JA. Sleep and risk-taking behavior in adolescents. Behav Sleep Med 2005;3:113-133.
37. Carley DW, Paviovic S, Janelidze M, Radulovacki M. Functional role for cannabinoids in respiratory stability during sleep. Sleep 2002;25:391-398.